Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Catheter Precision Inc. (VTAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VTAK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.18% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.99M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -0.65 | 52 Weeks Range 0.16 - 4.80 | Updated Date 06/30/2025 |
52 Weeks Range 0.16 - 4.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2416.78% |
Management Effectiveness
Return on Assets (TTM) -28.59% | Return on Equity (TTM) -136.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4332526 | Price to Sales(TTM) 6.21 |
Enterprise Value 4332526 | Price to Sales(TTM) 6.21 | ||
Enterprise Value to Revenue 9.01 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 12593900 | Shares Floating 9761987 |
Shares Outstanding 12593900 | Shares Floating 9761987 | ||
Percent Insiders 7.99 | Percent Institutions 4.67 |
Analyst Ratings
Rating 1 | Target Price 2 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Catheter Precision Inc.
Company Overview
History and Background
Catheter Precision, Inc. was founded in 2011. It focuses on developing and commercializing innovative technologies for electrophysiology procedures.
Core Business Areas
- Vascular Mapping and Navigation: Develops and sells systems for precise mapping and navigation of catheters within the heart, aiming to improve the accuracy and efficiency of cardiac ablation procedures. Its core product is the Rome system.
- 3D Cardiac Imaging: Provides tools that offer real-time 3D visualization of the heart's electrical activity, assisting physicians in identifying and targeting arrhythmia sources.
Leadership and Structure
The company has a management team led by a CEO. The structure includes departments for R&D, marketing, sales, and operations. More details about leadership can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- Competitors: Biosense Webster (JNJ), Abbott (ABT), Boston Scientific (BSX)
- Rome System: The Rome system is a 3D cardiac mapping and navigation system that provides physicians with detailed information about the heart's electrical activity. Market share data for the Rome system as a single product is difficult to ascertain. Competition includes companies like Biosense Webster (JNJ), Abbott (ABT) and Boston Scientific (BSX) which provide similar mapping solutions.
Market Dynamics
Industry Overview
The electrophysiology market is growing due to increasing prevalence of atrial fibrillation and other cardiac arrhythmias. Advances in technology and demand for less invasive procedures are driving market expansion.
Positioning
Catheter Precision aims to differentiate itself through innovative mapping and navigation technology that enhances procedural accuracy and efficiency. They are positioned as a smaller, specialized player in a market dominated by larger, more established companies.
Total Addressable Market (TAM)
The total addressable market for electrophysiology is expected to reach billions of dollars. Catheter Precision is positioned to capture a portion of this market through its specialized technology, though its current market share is small.
Upturn SWOT Analysis
Strengths
- Innovative Mapping Technology
- Focus on Electrophysiology
- Potential for improved clinical outcomes with precise mapping
- Experienced management team
Weaknesses
- Limited Financial Resources
- Small Market Share compared to competitors
- Reliance on single core product (Rome System)
- Dependence on regulatory approvals
Opportunities
- Growing Electrophysiology Market
- Partnerships with larger medical device companies
- Expansion into new geographic markets
- New product development (i.e. imaging, diagnostic catheters)
Threats
- Competition from larger medical device companies (Biosense Webster, Abbott, Boston Scientific)
- Technological advancements by competitors
- Regulatory changes
- Reimbursement pressures
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Catheter Precision faces significant competition from larger, well-established medical device companies. To succeed, they must continue to innovate and demonstrate the clinical and economic value of their technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on product adoption and market penetration. Financial statements will provide data on revenue growth over the past few years.
Future Projections: Future projections are subject to analyst estimates and company guidance. Access analyst reports for specific growth forecasts.
Recent Initiatives: Recent strategic initiatives would include product development, clinical studies, and marketing efforts. Check recent press releases and investor presentations for updates.
Summary
Catheter Precision is a small company in the competitive electrophysiology market with innovative mapping technology. The company is at a disadvantage, but has the opporutnity to grow. They need to continue product development, strategic partnerships, and gain market share. Managing cash flow and competition are important for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
- Investor Presentations
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catheter Precision Inc.
Exchange NYSE MKT | Headquaters Fort Mill, SC, United States | ||
IPO Launch date 2018-09-27 | CEO, Chief Commercial Officer & Executive Chairman Mr. David A. Jenkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 22 | |
Full time employees 22 | |||
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.